Connect with us

Media OutReach

More than 60% of Malaysians Lack Vitamin D Alpro Pharmacy Subsidises RM1.6 Million for Project :D to Tackle Malaysia’s Silent Vitamin D Crisis

Published

on

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 29 August 2025 – Despite Malaysia’s year-round sunshine, Vitamin D insufficiency has become a widespread and often overlooked health challenge. A systematic review published in the International Journal of Environmental Research and Public Health (2022) reported that 64% of Malaysians have suboptimal Vitamin D levels, while more than 20% are deficient. Pregnant women are among the most vulnerable, with a study in Nutrients (2022) finding that up to 96% of expectant mothers were deficient by the time of delivery. It can weaken bones, increase the risk of fractures and falls among the elderly, compromise immunity, affect mood and energy, and in pregnancy it is linked to gestational diabetes, pre-eclampsia, preterm birth, and impaired bone development in newborns.

(From Left: Assoc. Prof. Dr. Mohd Shahezwan Abd Wahab (Project leader and Deputy Dean of Research and Innovation, UiTM); Prof. Winnie Chee Siew Swee (Professor, Nutrition & Dietetics, IMU University; Director, Institute of Research, Development and Innovation, IRDI); Ms Elsie Low (General Manager of Powerlife Malaysia); Pharmacist Ng Yi Ling (Professional Care & Development Manager, Alpro Pharmacy); Dr. Ng Ming Lee (Medical Director, Alpro Clinic); Dr Nagammai Thiagarajan (Vice President, Malaysian Falls Prevention Network, MyFalls); Mr. Too Jia Leong (Managing Director, Global Science)

To confront this widespread and often overlooked health challenge, Alpro Pharmacy has launched Project 😀 with an RM1.6 million nationwide subsidy, making Vitamin D testing and education accessible to Malaysians. The initiative aims to screen 30,000 people, raise awareness, and provide personalised counselling by pharmacists, doctors, and dietitians.

Project 😀 will begin in September 2025 with 30 pilot outlets, before expanding nationwide in October 2025. Screening is priced at RM1 ONLY for high-risk groups (elderly, pregnant and breastfeeding mothers, or individuals with limited sun exposure) and RM15 for the general public (normal price RM35). Each test comes with professional counselling and a tailored health plan.

“Vitamin D deficiency is more than a nutritional issue; it is a public health challenge that affects immunity, mood, energy, and even the risk of falls among our elderly. At Alpro, we believe every Malaysian deserves access to the tools and care they need to live healthier, brighter lives. Project 😀 is our commitment to walk this journey together with the public — towards a healthier and vibrant Malaysia,” said Ph. Lim En Ni, Chief Pharmacist and Engagement Director of Alpro Pharmacy.

Supporting this mission, Powerlife, a leading health supplement provider in Malaysia, has stepped forward as the main partner of Project :D. They have contributed 300 advanced Vitamin D analysers to Alpro outlets nationwide. These devices, powered by Global Science’s handheld fluorescence technology, deliver accurate results within minutes and bridge the accessibility gap between costly laboratory tests and less reliable rapid kits.

To strengthen the initiative’s long-term impact, Alpro is also collaborating with two leading academic institutions. The International Medical University (IMU) will conduct research on Vitamin D’s role in maternal and infant health, while Universiti Teknologi MARA (UiTM) will study its impact on elderly care, particularly in preventing falls and fractures.

Our research is not just about data — it is about people. By understanding how Vitamin D shapes the health of mothers, babies, children & adolescents and the elderly, we can turn science into action. Through this collaboration with Alpro, we are taking meaningful steps to improve lives in Malaysia,” said Professor Winnie Chee, Professor of Nutrition & Dietetics at IMU and Director of the Institute of Research, Development and Innovation (IRDI).

Beyond screenings, Project 😀 will also roll out educational campaigns, community talks, and awareness programmes in partnership with MyFalls, focusing on fall prevention among the elderly and raising awareness of the crucial role Vitamin D plays in everyday wellness.

Malaysians are encouraged to take the first step towards better health by joining Project :D. Visit your nearest Alpro Pharmacy or Alpro Clinic to learn more and locate participating outlets. For updates and expert advice, follow Alpro Pharmacy’s official social media channels.
Hashtag: #AlproPharmacy

The issuer is solely responsible for the content of this announcement.

About Alpro Pharmacy

With a humble beginning starting with a single pharmacy outlet in the small town of Port Dickson in 2002, Alpro Pharmacy is now a diversified community chain pharmacy that provides comprehensive primary healthcare solutions via over 300 outlets including Alpro Pharmacy, Alpro Clinic, Alpro Physio and Alpro Baby, both online and offline, nationwide. It is supported by a team of more than 650 healthcare professionals, ranging from doctors, pharmacists, nutritionists, dietitians to physiotherapists and many other healthcare professionals.

Serving more than 3 million families in Malaysia, Alpro Pharmacy is the first and only community pharmacy in the country to provide RM1 million product liability insurance to safeguard the supply of genuine medications. With over 500,000 prescriptions filled per year, Alpro Pharmacy is also the largest prescription pharmacy chain in Malaysia.

For more information, please visit .

Advertisement

Media OutReach

Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia

Published

on

SINGAPORE – Media OutReach Newswire – 12 March 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to Cialis® (Tadalafil), a leading men’s health product from Eli Lilly and Company (“Lilly”) in Hong Kong, Macau and South Korea.

Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.

The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.

“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem

Published

on

HONG KONG SAR – Media OutReach Newswire – 12 March 2026 – Ingdan, Inc. (“Ingdan” or the “Company”, stock code: 400.HK; with its subsidiaries (the ”Group”)), a core supplier in the AI computing power supply chain and a leading application technology solutions provider, announces continued progress in strengthening its humanoid robotics ecosystem through an integrated embodied intelligence IC product matrix, supporting the industry’s transition toward large‑scale commercialization.

2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.

Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.

D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.

In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.

By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.

The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.

Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.

For investor and media enquiries
Please email to **@****an.com

Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech

The issuer is solely responsible for the content of this announcement.

Ingdan, Inc.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

Continue Reading

Media OutReach

Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events

Published

on

  • European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
  • With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.

Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.

Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.

Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD

Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.

The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.

Changan Standard: Proven in the Alps, Bound for the World

Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.

Hashtag: #Changan

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending